Cheng Qian, Tang Yishu, Yang Qing, Wang Erhua, Liu Jing, Li Xin
Department of Hematology, The Third Xiangya Hospital, Central South University, Changsha, 410013 Hunan China.
Department of Medicine, Yale New Haven Hospital, New Haven, CT USA.
Springerplus. 2016 Nov 29;5(1):2038. doi: 10.1186/s40064-016-3714-z. eCollection 2016.
Owing to the nature of acute illness and adverse effects derived from intensive chemotherapy, patients with hematological malignancies (HM) who are admitted to the Intensive Care Unit (ICU) often present with poor prognosis. However, with advances in life-sustaining therapies and close collaborations between hematologists and intensive care specialists, the prognosis for these patients has improved substantially. Many studies from different countries have examined the prognostic factors of these critically ill HM patients. However, there has not been an up-to-date review on this subject, and very few studies have focused on the prognosis of patients with HM admitted to the ICU in Asian countries. Herein, we aim to explore the current situation and prognostic factors in patients with HM admitted to ICU, mainly focusing on studies published in the last 10 years.
由于急性疾病的性质以及强化化疗产生的不良反应,入住重症监护病房(ICU)的血液系统恶性肿瘤(HM)患者往往预后较差。然而,随着生命维持疗法的进步以及血液科医生与重症监护专家之间的密切合作,这些患者的预后有了显著改善。来自不同国家的许多研究都探讨了这些重症HM患者的预后因素。然而,目前尚未有关于这一主题的最新综述,而且很少有研究关注亚洲国家入住ICU的HM患者的预后。在此,我们旨在探讨入住ICU的HM患者的现状和预后因素,主要关注过去10年发表的研究。